Dermatomyositis Treatment Market Size in the 7MM was ~USD 187 Million in 2023 and It is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Dermatomyositis Market Report
• The total diagnosed Dermatomyositis prevalence in the United States were around 38.5 thousand cases in 2023.
• The United States contributed to the largest diagnosed prevalent population of Dermatomyositis, acquiring ~54% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 29% and 17% of the total population share, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Dermatomyositis (5,272 Cases) cases followed by the UK (4,594 Cases), whereas Spain accounted for the lowest number of cases (3,053 Cases) in 2023.
• In 2023, it was estimated that there were around 15 thousand diagnosed cases in the age group of 40-59, followed by 13 thousand in 60-79 age group, 5,400 cases in 18-39 age group, 4,200 cases in 0-17 age group, and 1200 cases in 80 years and older in the US.
• According to DelveInsight estimates, in 2023 there were approximately 6,937 diagnosed prevalent cases of Mild type and about 5,476 cases of Moderate to severe type in Japan.
• In 2023, Dermatomyositis affected ~12 thousand males and ~26 thousand females in the United States.
• In 2023, DelveInsight analysis of the chronicity-specific data in the US revealed that 70% of people affected with Dermatomyositis have Chronic type, while 30% have the Acute Type.
• In Japan in 2023, comorbidity-specific cases accounted for the following percentages of diagnosed prevalent cases: ILD at 20%, CVD at 18%, cancer malignancy at 4%, and other conditions (including osteoporosis, dysphagia, Raynaud's syndrome, calcinosis, etc.) at 58%.
• The leading Dermatomyositis Companies such as AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Promising Dermatomyositis Therapies such as Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others

Get a Free sample for the Dermatomyositis Market Report @ Dermatomyositis Treatment Market- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dermatomyositis Overview
Dermatomyositis is a rare inflammatory myopathy characterized by muscle weakness and distinctive skin manifestations. This autoimmune disease primarily affects proximal muscles, leading to progressive muscle weakness in the shoulders, hips, and neck. Dermatomyositis symptoms include heliotrope rash (purplish discoloration around the eyes), Gottron's papules (red, scaly patches on knuckles), and photosensitivity. Patients often experience difficulty in climbing stairs, lifting objects, or rising from a seated position due to muscle inflammation. The exact cause of dermatomyositis remains unclear, but it is believed to involve immune system dysfunction, genetic predisposition, and environmental triggers. Diagnosis involves clinical evaluation, muscle biopsy, electromyography (EMG), and elevated muscle enzymes such as creatine kinase (CK). Magnetic resonance imaging (MRI) and antibody tests, including anti-Mi-2, anti-TIF1-γ, and anti-NXP2, help in confirming dermatomyositis.

Dermatomyositis Epidemiology Segmentation in the 7MM
• Total Prevalence of Dermatomyositis
• Prevalent Cases of Dermatomyositis by Severity
• Gender-specific Prevalence of Dermatomyositis
• Diagnosed Cases of Episodic and Chronic Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiology Forecast- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dermatomyositis Marketed Drugs
• OCTAGAM 10% (immunoglobulin): Octapharma
OCTAGAM 10% (immune globulin intravenous [human]) is the first and only intravenous immunoglobulin (IVIg) product indicated for the treatment of primary humoral immunodeficiency, chronic Immune Thrombocytopenic Purpura (ITP) and dermatomyositis. IVIG replacement therapy is the apparent treatment of choice for humoral primary immunodeficiency, such as dermatomyositis, as these patients cannot mount an effective immune response toward pathogens. Additionally, IVIg acts as a corticosteroid-sparing agent and represents a unique dermatomyositis treatment options for patients. They are safe and effective treatment options, especially in patients showing no response or incomplete response to corticosteroids or who experience severe side effects. It is made from healthy human blood with a high level of certain defensive substances (antibodies), which help fight infections, and is also used to increase the blood count (platelets) in persons with a certain blood disorder, ITP.

Dermatomyositis Emerging Drugs
• Brepocitinib: Priovant Therapeutics/Pfizer
Brepocitinib, being developed by Priovant Therapeutics, is an oral, once-daily dual inhibitor of TYK2 and JAK1. It targets the cytokine signaling pathways implicated in autoimmune diseases, including Type I and Type II interferon, IL-6, IL-12, and IL-23. This dual inhibition is intended to provide a broad suppression of these pathways, which are involved in the pathogenesis of dermatomyositis. Brepocitinib has shown promising results in several Phase II studies, demonstrating its efficacy and safety. Currently, it is being evaluated in a registrational Phase III trial specifically for dermatomyositis, aiming to address the significant unmet need for effective and convenient treatments for this condition.

• Efgartigimod: Argenx
Efgartigimod is an SC product combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20). Efgartigimod targets the neonatal Fc receptor (FcRn) as a first-in-class investigational antibody fragment. Efgartigimod binds to the neonatal Fc receptor and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing the degradation of IgG and pathological auto-antibodies without altering other immunoglobulins and albumin levels. It is undergoing a Phase III and II/III dermatomyositis clinical trials in participants with active IIM subtypes, including dermatomyositis. Further, the interim analysis of the first 30 patients of each subset is expected by 2024.

• NM-8074: NovelMed
NM-8074 (ruxoprubart) is a humanized monoclonal antibody from NovelMed Therapeutics that inhibits complement factor Bb, selectively blocking the alternative complement pathway while preserving classical and lectin pathways. In Phase II trials, it has demonstrated improved hemoglobin levels, reduced LDH, and transfusion independence in PNH patients. NM-8074 is also being evaluated for aHUS and dermatomyositis and remains investigational with orphan drug designation.

Dermatomyositis Therapies and Companies
• Brepocitinib: Priovant Therapeutics, Inc.
• Lenabasum: Corbus Pharmaceuticals
• HIZENTRA: CSL Behring
• Ravulizumab: Alexion
• Lenabasum: Corbus Pharmaceuticals Inc.
• IMO-8400: Idera Pharmaceuticals
• GLPG3667: Galapagos NV
• M5049: EMD Serono
• human immunoglobulin G: CSL Behring
• PF-06823859: Pfizer
• Octagam: Octapharma
• KZR-616: Kezar Life Sciences, Inc.
• GB-0998: Japan Blood Products Organization
• H.P. Acthar Gel: Mallinckrodt
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• tocilizumab: Genentech, Inc.
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Biogen

Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis Drugs Market- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dermatomyositis Market Outlook
There is no cure for dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient's quality of life. The recent approval of OCTAGAM and the presence of several management guidelines, including the British Society for Rheumatology guideline, the Japanese Society of Rheumatology guideline, and others, have revolutionized the treatment landscape of dermatomyositis. Several other off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are used individually or in combination to eliminate symptoms.

Dermatomyositis Market Strengths
• A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAs targeting C5 complement, IFNβ1, FcRn, and others.
• Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients

Dermatomyositis Market Opportunities
• Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression.
• The lack of curative and effective therapies allows pharma players to conduct trials and bring novel, disease-modifying therapies.

Scope of the Dermatomyositis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement

To know more about Dermatomyositis companies working in the treatment market, visit @ Dermatomyositis Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Dermatomyositis Market Report Introduction
2. Executive Summary for Dermatomyositis
3. SWOT analysis of Dermatomyositis
4. Dermatomyositis Patient Share (%) Overview at a Glance
5. Dermatomyositis Market Overview at a Glance
6. Dermatomyositis Disease Background and Overview
7. Dermatomyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Dermatomyositis
9. Dermatomyositis Current Treatment and Medical Practices
10. Dermatomyositis Unmet Needs
11. Dermatomyositis Emerging Therapies
12. Dermatomyositis Market Outlook
13. Country-Wise Dermatomyositis Market Analysis (2020-2034)
14. Dermatomyositis Market Access and Reimbursement of Therapies
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Dermatomyositis Appendix
18. Dermatomyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.